Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 13 of 13« First...910111213

The cost of cancer: new drugs show success at a steep price

Newer cancer drugs that enlist the body’s immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year.

Read More »

Troubled Sucampo Pays $200 Million Upfront for Rare Disease Biotech Vtesse

Rockville, Md.-based Sucampo Pharmaceuticals has acquired privately held Gaithersburg, Md.-based Vtesse.

Read More »

Astellas Takes Out Belgium Biotech in Deal Worth $853 Million

Astellas Pharma struck a deal valued at up to $853 million to acquire Belgium-based Ogeda SA, a privately held clinical-stage drug discovery company, and its lead drug candidate fezolinetant.

Read More »

Page 13 of 13« First...910111213

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation